HTG Molecular Diagnostics, Inc. (HTGMQ)

Market Cap	221.00 -100.0%
Revenue (ttm)	6.21M -28.2%
Net Income	-20.15M
EPS	-15.79
Shares Out	2.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	592
Average Volume	2,042
Open	0.0001
Previous Close	n/a
Day's Range	0.0001 - 0.0001
52-Week Range	0.0000 - 0.0010
Beta	-67.68
RSI	49.75
Earnings Date	n/a

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company dist...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1997
• Employees: 54
• Stock Exchange: OTCMKTS
• Ticker Symbol: HTGMQ

Financial Performance

In 2022, HTG Molecular Diagnostics's revenue was $6.37 million, a decrease of -28.52% compared to the previous year's $8.91 million. Losses were -$21.59 million, 26.0% more than in 2021.